Advice
In the absence of a submission from the holder of the marketing authorisation.
paclitaxel (Abraxane®) is not recommended for use within NHS Scotland for the treatment of metastatic breast cancer in patients who have failed first-line treatment for metastatic disease and for whom standard anthracycline containing therapy is not indicated.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHS Scotland.
Download detailed advice48KB (PDF)
Medicine details
- Medicine name:
- paclitaxel (Abraxane)
- SMC ID:
- 556/09
- Indication:
- Metastatic breast cancer
- Pharmaceutical company
- Abraxis Bioscience Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 11 May 2009